Compare GSK plc (GSK) vs Hewlett Packard Enterprise Co (HPE) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

HPE stock declined 8.45% to $45.37 amid a broader AI hardware sector pullback, though technical indicators remain bullish with strong support at $45. The company shows solid fundamentals with three consecutive earnings beats and robust AI infrastructure demand driving a record $6B backlog. Revenue grew to $34.3B in 2025 while maintaining a 33.9% gross margin, though net income dropped significantly to $57M due to acquisition-related costs.

HPE presents a compelling opportunity with analyst consensus target of $69.69 (54% upside) and strong AI infrastructure positioning, but faces execution risks from the Juniper integration and volatile cash flow trends. The stock's current valuation at 44.29 P/E appears elevated relative to historical norms, requiring careful monitoring of margin expansion and debt management.